Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists, has announced its participation in the upcoming Leerink Partners Global Healthcare Conference 2025. The conference will be held from March 10-12, 2025, at the W South Beach Hotel in Miami, FL.
The company, which specializes in treatments for bradykinin-mediated diseases including hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), will provide a live audio webcast of their presentation through their investor relations website. The recording will remain accessible for 30 days following the event.
Pharvaris (Nasdaq: PHVS), un'azienda biofarmaceutica in fase avanzata focalizzata sullo sviluppo di antagonisti orali del recettore della bradychinina B2, ha annunciato la sua partecipazione alla prossima Conferenza Globale sulla Salute di Leerink Partners 2025. La conferenza si terrà dal 10 al 12 marzo 2025, presso il W South Beach Hotel a Miami, FL.
L'azienda, specializzata nei trattamenti per le malattie mediate dalla bradychinina, tra cui l'angioedema ereditario (HAE) e l'angioedema acquisito a causa della carenza di inibitore C1 (AAE-C1INH), fornirà una trasmissione audio in diretta della loro presentazione attraverso il sito web per le relazioni con gli investitori. La registrazione rimarrà accessibile per 30 giorni dopo l'evento.
Pharvaris (Nasdaq: PHVS), una compañía biofarmacéutica en fase avanzada centrada en el desarrollo de antagonistas orales del receptor de bradiquinina B2, ha anunciado su participación en la próxima Conferencia Global de Salud de Leerink Partners 2025. La conferencia se llevará a cabo del 10 al 12 de marzo de 2025, en el W South Beach Hotel en Miami, FL.
La compañía, que se especializa en tratamientos para enfermedades mediadas por bradiquinina, incluyendo angioedema hereditario (HAE) y angioedema adquirido debido a la deficiencia de inhibidor C1 (AAE-C1INH), ofrecerá una transmisión de audio en vivo de su presentación a través de su sitio web de relaciones con inversores. La grabación estará disponible durante 30 días después del evento.
Pharvaris (Nasdaq: PHVS)는 구강 브라디키닌 B2 수용체 길항제 개발에 집중하는 후기 단계의 생물 제약 회사로, 다가오는 Leerink Partners 글로벌 헬스케어 컨퍼런스 2025에 참여한다고 발표했습니다. 이 컨퍼런스는 2025년 3월 10일부터 12일까지 마이애미의 W South Beach Hotel에서 개최됩니다.
브라디키닌 매개 질환, 즉 유전성 혈관부종 (HAE) 및 C1 억제제 결핍으로 인한 후천성 혈관부종 (AAE-C1INH) 치료를 전문으로 하는 이 회사는 투자자 관계 웹사이트를 통해 발표의 라이브 오디오 웹캐스트를 제공할 예정입니다. 녹음은 이벤트 종료 후 30일 동안 접근 가능합니다.
Pharvaris (Nasdaq: PHVS), une société biopharmaceutique en phase avancée axée sur le développement d'antagonistes oraux des récepteurs de bradykinine B2, a annoncé sa participation à la prochaine Conférence Mondiale sur la Santé de Leerink Partners 2025. La conférence se tiendra du 10 au 12 mars 2025, à l'hôtel W South Beach à Miami, FL.
L'entreprise, spécialisée dans les traitements des maladies médiées par la bradykinine, y compris l'angioedème héréditaire (HAE) et l'angioedème acquis dû à une carence en inhibiteur C1 (AAE-C1INH), proposera une diffusion audio en direct de sa présentation via son site web de relations avec les investisseurs. L'enregistrement sera accessible pendant 30 jours après l'événement.
Pharvaris (Nasdaq: PHVS), ein biopharmazeutisches Unternehmen in der späten Entwicklungsphase, das sich auf die Entwicklung von oralen Bradykinin-B2-Rezeptor-Antagonisten konzentriert, hat seine Teilnahme an der bevorstehenden Leerink Partners Global Healthcare Conference 2025 angekündigt. Die Konferenz findet vom 10. bis 12. März 2025 im W South Beach Hotel in Miami, FL, statt.
Das Unternehmen, das auf Behandlungen für bradykininvermittelte Erkrankungen wie hereditäres Angioödem (HAE) und erworbenes Angioödem aufgrund eines C1-Inhibitor-Mangels (AAE-C1INH) spezialisiert ist, wird eine Live-Audioübertragung ihrer Präsentation über ihre Investor-Relations-Website bereitstellen. Die Aufzeichnung bleibt 30 Tage nach der Veranstaltung zugänglich.
- None.
- None.
ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that its management will participate in the Leerink Partners Global Healthcare Conference 2025, taking place from March 10-12, 2025, at the W South Beach Hotel in Miami, FL. Details are as follows:
| Format: | Fireside Chat |
| Representative: | Berndt Modig, CEO of Pharvaris |
| Date & Time: | Monday, March 10, 9:20 a.m. ET |
A live audio webcast will also be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations. The audio replay will be available on Pharvaris’ website for 30 days following the presentation.
About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy and placebo-like tolerability with the convenience of an oral therapy to prevent and treat HAE attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit https://pharvaris.com/.
FAQ
When and where is Pharvaris (PHVS) presenting at the Leerink Partners Conference 2025?
How can investors access Pharvaris's (PHVS) presentation at the Leerink Conference?
How long will Pharvaris's (PHVS) Leerink Conference presentation be available for replay?
What medical conditions is Pharvaris (PHVS) developing treatments for?
